Cardiac involvement in eosinophilic granulomatosis with polyangitis (Churg Strauss) (RCD code: I-3A.7a)
Journal Title: Journal of Rare Cardiovascular Diseases - Year 2013, Vol 1, Issue 3
Abstract
Eosinophilic granulomatosis with polyangitis – EGPA (previously known as Churg‑Strauss syndrome) is a rare, systemic, necrotizing small‑vessel vasculitis with accompanying bronchial asthma, eosinophilia and eosinophilic tissue infiltration of various tissues with granuloma formation. The pathognomonic laboratory feature of EGPA is prominent peripheral eosinophilia that commonly exceed 1,500 cells/μl, and the presence in approximately 40% of patients of the antineutrophil autoantibodies (ANCA). EGPA is one of the most common of the systemic vasculitides to affect the heart and if present it deteriorates the prognosis of the disease and increases mortality. Cardiac involvement varies widely ranging from 16–92% and is more common in ANCA negative patients. The cardiac manifestations varies in its clinical presentation. It may present as myocarditis with cardiomyopathy, pericarditis with pericardial effusion (up to 25% of patients), heart failure (18%),varies ventricular and supraventricular arrhythmias, valve involvement and sudden cardiac death. Epicardial coronary arteries involvement is rare, however, coronary angiography should be considered in patients presenting with angina symptoms to rule out important coronary vessels stenosis. Imaging techniques as transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR) may help in establishing the diagnosis of EGPA. The significance of often detected cardiac damage in CMR without clinical manifestation remains uncertain, however, some preliminary studies suggest that, these patients should be treated more intensively to prevent further cardiac involvement.The main treatment of EGPA consist of corticosteroids and additional immunosuppression in patients with worse prognosis. In differential diagnosis other forms of vasculitides and hypereosinophilic syndromes (HES) that may also affect the heart should be excluded.
Authors and Affiliations
Wojciech Szczeklik, Tomasz Miszalski-Jamka
Keywords
Related Articles
- EP ID EP245385
- DOI 10.20418/jrcd.vol1no3.56
- Views 68
- Downloads 0
Establishing the optimal dose of nitric oxide in acute vasoreactivity testing in patients with pulmonary hypertension with use of the Bronchial Control Treatment System (RCD code: II)
The key point in the diagnostic algorithm for pulmonary hypertension plays the pulmonary reactivity testing, the agent most frequently used in the test is inhaled nitric oxide (iNO). Various dosages of iNO were used in a...
World Rare Disease Day – 29th of February 2016 III Conference of Rare Cardiovascular Diseases at John Paul II Hospital in Krakow
The third Conference of Rare Cardiovascular Diseases took place at the John Paul II Hospital in Krakow, Poland on the 29th of February 2016. The conference was organized as part of the World Rare Disease Day 2016 annuall...
55 years old patient with congenital heart malformation (RCD code: IV-1B.1a)
Cor triatriatum is a rare congenital anomaly where the left or right atrium is subdivided by a thin membrane, resulting in three atrial chambers. We present a case of 55 years old female who presented progressive dyspnea...
Highlights from the Polish Pulmonary Hypertension Patients and their Friends Meeting in Krakow
Annual Meeting of the Pulmonary Hypertension Patients and their Friends organized by Pulmonary Hypertension Association (PHA) of Poland was held on June 11, 2016 at the Department of Cardiac and Vascular Diseases of the...
Ebstein Anomaly
Ebstein anomaly (EA) is a rare congenital malformation of the heart that is characterized by apical displacement of the septal and posterior tricuspid valve leaflets, with atrialization of the right ventricle and variabl...